NVS Jan 2025 115.000 call
| Previous close | 8.89 |
| Open | 8.89 |
| Bid | 7.30 |
| Ask | 7.60 |
| Strike | 115.00 |
| Expiry date | 2025-01-17 |
| Day's range | 8.89 - 8.89 |
| Contract range | N/A |
| Volume | |
| Open interest | 581 |
ZacksNovartis to License VYGR's Capsid for Gene Therapy in Neurology
NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.
Insider MonkeyJim Cramer Says It Will Take Time For Novartis AG (NVS) To ‘Get The Attention Of Investors’
We recently compiled a list of the Top 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other stocks on Jim Cramer’s radar. Jim Cramer often reflects on how he would reform the American education system if it were up to […]
GlobeNewswireVoyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royaltiesLEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE: NVS) has agreed to license a novel capsid generated from Voyager’s TRACER™ capsid discovery platform for use in a gene therapy program
